198 related articles for article (PubMed ID: 34904498)
1. Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma.
Wong XY; Chng WJ; Aziz MIA; Ng K
Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):207-215. PubMed ID: 34904498
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.
Narsipur N; Bulla S; Yoo C; Do B; Tran K; Gu D; Zhong L; Wilson L
J Manag Care Spec Pharm; 2021 Dec; 27(12):1691-1702. PubMed ID: 34818089
[No Abstract] [Full Text] [Related]
3. Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma.
Zhang TT; Wang S; Wan N; Zhang L; Zhang Z; Jiang J
Clin Ther; 2018 Jul; 40(7):1122-1139. PubMed ID: 30006069
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma.
Patel KK; Giri S; Parker TL; Bar N; Neparidze N; Huntington SF
J Clin Oncol; 2021 Apr; 39(10):1119-1128. PubMed ID: 33411586
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
Jakubowiak AJ; Campioni M; Benedict Á; Houisse I; Tichy E; Giannopoulou A; Aggarwal SK; Barber BL; Panjabi S
J Med Econ; 2016 Nov; 19(11):1061-1074. PubMed ID: 27224006
[TBL] [Abstract][Full Text] [Related]
6. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma.
Alhaj Moustafa M; Parrondo R; Abdulazeez MF; Roy V; Sher T; Alegria VR; Warsame RM; Fonseca R; Rasheed A; Gonsalves WI; Kourelis T; Kapoor P; Buadi FK; Dingli D; Hayman SR; Reeder CB; Chanan-Khan AA; Ailawadhi S
Anticancer Drugs; 2024 Jan; 35(1):63-69. PubMed ID: 37067996
[TBL] [Abstract][Full Text] [Related]
7. Daratumumab plus lenalidomide and dexamethasone
Dimopoulos MA; San-Miguel J; Belch A; White D; Benboubker L; Cook G; Leiba M; Morton J; Ho PJ; Kim K; Takezako N; Moreau P; Kaufman JL; Sutherland HJ; Lalancette M; Magen H; Iida S; Kim JS; Prince HM; Cochrane T; Oriol A; Bahlis NJ; Chari A; O'Rourke L; Wu K; Schecter JM; Casneuf T; Chiu C; Soong D; Sasser AK; Khokhar NZ; Avet-Loiseau H; Usmani SZ
Haematologica; 2018 Dec; 103(12):2088-2096. PubMed ID: 30237262
[TBL] [Abstract][Full Text] [Related]
8. Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTOR.
Zeng X; Peng L; Peng Y; Tan C; Wan X
Clin Ther; 2020 Feb; 42(2):251-262.e5. PubMed ID: 31973936
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma.
Goudarzi Z; Shahtaheri RS; Najafpour Z; Hamedifar H; Ebrahimi H
Cost Eff Resour Alloc; 2024 Feb; 22(1):17. PubMed ID: 38419054
[TBL] [Abstract][Full Text] [Related]
10. Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data.
Campioni M; Agirrezabal I; Hajek R; Minarik J; Pour L; Spicka I; Gonzalez-McQuire S; Jandova P; Maisnar V
Eur J Health Econ; 2020 Mar; 21(2):219-233. PubMed ID: 31673898
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial.
Plesner T; Dimopoulos MA; Oriol A; San-Miguel J; Bahlis NJ; Rabin N; Suzuki K; Yoon SS; Ben-Yehuda D; Cook G; Goldschmidt H; Grosicki S; Qin X; Fastenau J; Garvin W; Carson R; Renaud T; Gries KS
Br J Haematol; 2021 Jul; 194(1):132-139. PubMed ID: 33822368
[TBL] [Abstract][Full Text] [Related]
12. Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers.
Bayani DB; Lin YC; Nagarajan C; Ooi MG; Tso ACY; Cairns J; Wee HL
Pharmacoecon Open; 2024 Jun; ():. PubMed ID: 38900407
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile.
Aceituno S; Gozalbo I; Appierto M; Lizán L
Medwave; 2018 Jun; 18(3):e7220. PubMed ID: 29958267
[TBL] [Abstract][Full Text] [Related]
14. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos MA; Oriol A; Nahi H; San-Miguel J; Bahlis NJ; Usmani SZ; Rabin N; Orlowski RZ; Komarnicki M; Suzuki K; Plesner T; Yoon SS; Ben Yehuda D; Richardson PG; Goldschmidt H; Reece D; Lisby S; Khokhar NZ; O'Rourke L; Chiu C; Qin X; Guckert M; Ahmadi T; Moreau P;
N Engl J Med; 2016 Oct; 375(14):1319-1331. PubMed ID: 27705267
[TBL] [Abstract][Full Text] [Related]
15. Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial.
Dolph M; Tremblay G; Leong H
Pharmacoeconomics; 2021 Nov; 39(11):1309-1325. PubMed ID: 34368938
[TBL] [Abstract][Full Text] [Related]
16. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies.
Mateos MV; Spencer A; Nooka AK; Pour L; Weisel K; Cavo M; Laubach JP; Cook G; Iida S; Benboubker L; Usmani SZ; Yoon SS; Bahlis NJ; Chiu C; Ukropec J; Schecter JM; Qin X; O'Rourke L; Dimopoulos MA
Haematologica; 2020; 105(2):468-477. PubMed ID: 31221782
[TBL] [Abstract][Full Text] [Related]
17. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.
Dimopoulos MA; Oriol A; Nahi H; San-Miguel J; Bahlis NJ; Usmani SZ; Rabin N; Orlowski RZ; Suzuki K; Plesner T; Yoon SS; Ben Yehuda D; Richardson PG; Goldschmidt H; Reece D; Ahmadi T; Qin X; Garvin Mayo W; Gai X; Carey J; Carson R; Moreau P
J Clin Oncol; 2023 Mar; 41(8):1590-1599. PubMed ID: 36599114
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study.
Suzuki K; Dimopoulos MA; Takezako N; Okamoto S; Shinagawa A; Matsumoto M; Kosugi H; Yoon SS; Huang SY; Qin X; Qi M; Iida S
Blood Cancer J; 2018 May; 8(4):41. PubMed ID: 29712896
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
Usmani SZ; Cavenagh JD; Belch AR; Hulin C; Basu S; White D; Nooka A; Ervin-Haynes A; Yiu W; Nagarwala Y; Berger A; Pelligra CG; Guo S; Binder G; Gibson CJ; Facon T
J Med Econ; 2016; 19(3):243-58. PubMed ID: 26517601
[TBL] [Abstract][Full Text] [Related]
20. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
Facon T; Kumar SK; Plesner T; Orlowski RZ; Moreau P; Bahlis N; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; O'Dwyer M; Perrot A; Venner CP; Weisel K; Mace JR; Raje N; Tiab M; Macro M; Frenzel L; Leleu X; Ahmadi T; Wang J; Van Rampelbergh R; Uhlar CM; Tromp B; Delioukina M; Vermeulen J; Usmani SZ
Lancet Oncol; 2021 Nov; 22(11):1582-1596. PubMed ID: 34655533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]